Recent Press Releases

Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology

Companies to advance a potentially transformative treatment approach for genetic diseases of the eye AGTC to receive $124M upfront, with potential future milestone payments and royalties AGTC to host...

Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages

- Results demonstrated programmed cell death in KS tumor cells and anti-HIV activity - - Reinforces therapeutic potential of targeting activated macrophages via the CD206 receptor - July 02, 2015...

Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets

July 02, 2015 04:30 PM Eastern Daylight Time NEW YORK--()--Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer's new...

ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders

SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...

OptiNose Announces Positive Results of Phase III Trial for OPN-375

OPN-375, in Development for Chronic Rhinosinusitis with and without Nasal Polyps, Demonstrated Statistically Significant Benefits in Patients with Nasal Polyps June 24, 2015 08:30 AM Eastern Daylight...

A Gel That Can Make Drugs Last Longer, A*STAR Study

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have developed a drug-delivering hydrogel to treat chronic diseases such as hepatitis C, a liver disease that kills...

Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery of Apomorphine to TurnParkinson's Disease Patients from the OFF to the ON State

CTH-300 Clinical Trial to Assess Effectiveness and Safety of APL-130277 Monday, June 29, 2015 TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the...

Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders

06.23.2015 - New Interim Data from Ongoing Phase 1 Study in Hemophilia Subjects Demonstrate an up to 86% AT Knockdown and a Re-Balancing of Hemostasis with Normalization of Thrombin Generation up to...

MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer

July 21, 2014 07:00 AM Eastern Daylight Time WALTHAM, Mass.--()--MicroCHIPS, Inc., a developer of implantable drug delivery devices, today announced that its Board of Directors has...

Cynapsus Therapeutics' APL-130277 Improved Parkinson's Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement Disorders

June 25, 2015 APL-130277, Sublingual Apomorphine, for On-Demand Treatment of OFF Episodes Associated with Parkinson's Disease TORONTO – (Marketwired) – Cynapsus Therapeutics Inc....

Acorda Presents Data on Inhaled Levodopa Therapy CVT-301 at International Congress of Parkinson's Disease and Movement Disorders

06/16/2015 Acorda Therapeutics, Inc.(Nasdaq:ACOR) today presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF...

Teva and Microchips Biotech Announce Partnership to Enhance Patient Outcomes through Digital Drug Delivery Technology

--Electronic Microchip-Based Implant Technology Delivers Medicines over Months and Years, Improving Adherence and Compliance for Patients --Promising Innovative Technology Offers Potential Across...

Oraya Therapeutics' IRay® Radiotherapy System Wins Silver at 2015 Medical Design Excellence Awards

NEWARK, Calif., June 16, 2015 – Oraya Therapeutics Inc. and Bridge Design announced today that the Oraya IRay® Radiotherapy System has won the Silver award in the radiological and...

Heron Therapeutics Initiates Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain

June 16, 2015 08:00 AM Eastern Daylight Time REDWOOD CITY, Calif.--()--Heron Therapeutics, Inc. (NASDAQ: HRTX) announced today that it has initiated a Phase 2 clinical trial of HTX-011,...

Tonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache

-- Frequent episodic tension-type headache estimated to afflict 75 million Americans -- -- Top-line results expected 4Q 2015 -- NEW YORK, June 16, 2015-- Tonix Pharmaceuticals Holding Corp. (TNXP)...

KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP

Company to Host Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa, June 11, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty...

Oculus Innovative Sciences Receives FDA Clearance for Novel Atopic Dermatitis Dermatology Product

PETALUMA, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of...

PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth

New Investor CRV Leads Round to Push for a Better Pharmacy BOSTON, June 3, 2015 /PRNewswire/ -- PillPack, the pharmacy that simplifies medication management, today announced it has completed a $50...

Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler® (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla™ in the UK

Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy...

OncoSec Medical Announces $13.6 Million Registered Direct Offering

SAN DIEGO, June 3, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has...